首页> 外文期刊>Papillomavirus Research >HPV E6 oncoproteins and nucleic acids in neck lymph node fine needle aspirates and oral samples from patients with oropharyngeal squamous cell carcinoma
【24h】

HPV E6 oncoproteins and nucleic acids in neck lymph node fine needle aspirates and oral samples from patients with oropharyngeal squamous cell carcinoma

机译:口咽鳞状细胞癌患者颈部淋巴结细针抽吸物和口腔样品中的HPV E6癌蛋白和核酸

获取原文
           

摘要

Commercial assays measuring HPV E6 viral oncoproteins, E6/E7 mRNA or DNA were used to test neck lymph node fine needle aspirates (FNA) and oropharyngeal samples (saliva and oral swabs) from 59 Canadian patients with oropharyngeal squamous cell carcinomas (OPSCC). Overall agreements of p16 antigen staining of tumors to FNA tested for OncoE6?, Aptima HPV E6/E7 mRNA and cobas HPV DNA were 81.4% (k 0.53), 94.9% (k 0.83) and 91.1% (k 0.73) respectively. Using HPV presence in a subset of 25 tumors as the comparator, overall agreement was 64.0% (k 0.08) with OncoE6?, 88.0% (k 0.65) with Aptima HPV E6/E7 mRNA and 91.7% (k 0.70) with cobas HPV DNA. HPV testing of oropharyngeal samples yielded lower agreements with tumor markers; 23.7–24.0% (k 0.02), 55.9–68.0% (k 0.24–0.37) and 78.9–86.9% (k 0.49–0.58) in the 3 respective tests. HPV 16 was present in 93.7–100% of the samples tested and showed 100% genotype agreement between FNA and tumors. The high rates for HPV E6 oncoproteins and E6/E7 mRNA suggests most patients were experiencing transcriptionally active HPV-related OPSCC. Results from these commercial assays performed on FNA but not oropharyngeal samples showed moderate to very good agreements with p16 and HPV testing of tumors.
机译:商业检测HPV E6病毒癌蛋白,E6 / E7 mRNA或DNA的方法用于测试59例加拿大口咽鳞状细胞癌(OPSCC)患者的颈部淋巴结细针抽吸物(FNA)和口咽样品(唾液和口腔拭子)。对FNA进行肿瘤p16抗原染色的总体一致性测试为OncoE6α,Aptima HPV E6 / E7 mRNA和cobas HPV DNA,分别为81.4%(k 0.53),94.9%(k 0.83)和91.1%(k 0.73)。使用HPV在25个肿瘤中的子集作为比较,与OncoE6?的总体一致性为64.0%(k 0.08),与Aptima HPV E6 / E7 mRNA的总体一致性为88.0%(k 0.65),与cobas HPV DNA的总体一致性为91.7%(k 0.70) 。口咽样品的HPV检测与肿瘤标志物的一致性较低。在3个测试中,分别为23.7–24.0%(k 0.02),55.9–68.0%(k 0.24–0.37)和78.9–86.9%(k 0.49–0.58)。 HPV 16存在于93.7–100%的测试样本中,并显示出FNA与肿瘤之间100%的基因型一致性。 HPV E6癌蛋白和E6 / E7 mRNA的高发生率表明大多数患者正在经历转录活性HPV相关的OPSCC。这些在FNA上进行的商业化检测结果,但对口咽样本却没有,显示出与p16和HPV肿瘤检测具有中等至非常好的一致性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号